Skip to main content
Article thumbnail
Location of Repository

Metastasis Suppressors and the Tumor Microenvironment

By Thomas M. Bodenstine and Danny R. Welch

Abstract

The most dangerous attribute of cancer cells is their ability to metastasize. Throughout the process of metastasis, tumor cells interact with other tumor cells, host cells and extracellular molecules. This brief review explores how a new class of molecules – metastasis suppressors – regulate tumor cell–microenvironmental interactions. Data are presented which demonstrate that metastasis suppressors act at multiple steps of the metastatic cascade. A brief discussion for how metastasis suppressor regulation of cellular interactions might be exploited is presented

Topics: Review Paper
Publisher: Springer Netherlands
OAI identifier: oai:pubmedcentral.nih.gov:2654358
Provided by: PubMed Central

Suggested articles

Citations

  1. A et al (2005) Expression of the breast cancer metastasis suppressor gene, BRMS1, in human breast carcinoma: lack of correlation with metastasis to axillary lymph nodes.
  2. A et al (2006) Interaction of KAI1 on tumor cells with DARC on vascular endothelium leads to metastasis suppression.
  3. (2004). A new look at an old problem: the survival and organ-specific growth of metastases.
  4. (1996). A novel src- and rassuppressed protein kinase C substrate associated with cytoskeletal architecture.
  5. (2006). A twist for survival and cancer progression.
  6. (2001). Analysis of mechanisms underlying BRMS1 suppression of metastasis.
  7. (2005). Anoikis and survival connections in the tumor microenvironment: Is there a role in prostate cancer metastasis?
  8. (2004). Breast cancer metastasis suppressor 1 (BRMS1) forms complexes with retinoblastoma-binding protein 1 (RBP1) and the mSin3 histone deacetylase complex and represses transcription.
  9. (2006). Breast cancer metastasis suppressor 1 (BRMS1) is stabilized by the Hsp90 chaperone.
  10. (2006). Breast cancer metastasis suppressor 1 functions as a corepressor by enhancing histone deacetylase 1-mediated deacetylation of RelA/p65 and promoting apoptosis.
  11. (2001). Breast cancer metastatic potential correlates with a breakdown in homospecific and heterospecific gap junctional intercellular communication.
  12. (2004). Breast cancer metastatic potential: Correlation with increased heterotypic gap junctional intercellular communication between breast cancer cells and osteoblastic cells.
  13. Cabioglu N et al (2007) Manipulating the chemokine–chemokine receptor network to treat cancer.
  14. Capodanno A et al (2006) High level of messenger RNA for BRMS1 in primary breast carcinomas is associated with poor prognosis.
  15. (2005). Carcinoma invasion and metastasis: A role for epithelial–mesenchymal transition?
  16. (2001). Cell adhesion in tumor invasion and metastasis: loss of the glue is not enough.
  17. Chambers AF et al (2001) Solitary cancer cells as a possible source of tumour dormancy?
  18. (1997). Changing views of the role of matrix metalloproteinases in metastasis.
  19. Chiang LC et al (2003) Histone deacetylase inhibitor up-regulates RECK to inhibit MMP-2 activation and cancer cell invasion.
  20. (1994). Differential suppression of mammary and prostate cancer metastasis by human chromosomes 17 and 11. Cancer Res 54:6249–6256
  21. (2002). Dissemination and growth of cancer cells in metastatic sites.
  22. (1998). Distinct patterns of E-cadherin CpG island methylation in papillary, follicular, Hurthle’s cell, and poorly differentiated human thyroid carcinoma.
  23. (2007). Do we need to redefine a cancer metastasis and staging definitions? Breast Disease 26:3–12
  24. (2006). Dormancy of solitary metastatic cells.
  25. (1997). Effects of TIMP-2 gene transfection on biological behaviors of a metastatic human lung carcinoma cell line. Zhonghua Yi Xue Za Zhi 77:652–656
  26. El-Deiry WS (2003) TRAIL and apoptosis induction by TNF-family death receptors.
  27. Elkahloun AG et al (2007) Nm23-H1 suppresses tumor cell motility by down-regulating the lysophosphatidic acid receptor EDG2.
  28. Elshourbagy NA et al (2001) AXOR12: A novel human G protein-coupled receptor, activated by the peptide KiSS-1.
  29. (2007). Emerging roles of proteases in tumour suppression.
  30. (2007). Epithelial– mesenchymal and mesenchymal–epithelial transitions in carcinoma progression.
  31. (2002). Epithelial–mesenchymal transitions in tumour progression.
  32. (2003). ERK(MAPK) activity as a determinant of tumor growth and dormancy; regulation by p38(SAPK).
  33. (1988). Evidence for a novel gene associated with low tumor metastatic potential.
  34. (2006). Exploring a new twist on tumor metastasis.
  35. (2000). Functional evidence for a novel human breast carcinoma metastasis suppressor, BRMS1, encoded at chromosome 11q13.
  36. (1999). Gap junctions: more roles and new structural data.
  37. (1994). Gelatinases and metalloproteinase inhibitor secreted by murine colonic carcinoma cells with differing metastatic potential.
  38. Goldberg SF et al (2002) Suppression of human melanoma metastasis by the metastasis suppressor gene,
  39. (1991). High levels of p19/ nm23 protein in neuroblastoma are associated with advanced stage disease and with N-myc gene amplification.
  40. (1999). Identification and characterization of candidate prostate cancer metastasis-suppressor genes encoded on human chromosome 17. Cancer Res 59:5483–5487
  41. (1974). Immune stimulation-inhibition of experimental cancer metastasis.
  42. (2002). Integrin cytoplasmic domain-associated protein 1α (ICAP-1α) interacts directly with the metastasis suppressor nm23-H2, and both Metastasis suppressors and microenvironment 9proteins are targeted to newly formed cell adhesion sites upon integrin engagement.
  43. (2000). Intravascular origin of metastasis from the proliferation of endothelium-attached tumor cells: a new model for metastasis.
  44. (2006). Invadopodia: specialized cell structures for cancer invasion.
  45. (2004). Involvement of histone deacetylation in ras-induced down-regulation of the metastasis suppressor RECK.
  46. (1996). KiSS-1, a novel human malignant melanoma metastasis-suppressor gene.
  47. KT et al (2008) BRMS1 suppresses breast cancer experimental metastasis to multiple 10 T.M. Bodenstine, D.R. Welchorgans by inhibiting several steps of the metastatic process.
  48. (1997). Localization of prostate cancer metastasis-suppressor activity on human chromosome 17. Prostate 33:271–280
  49. (2006). Loss of BRMS1 protein expression predicts reduced disease-free survival in hormone receptor negative and HER2 positive subsets of breast cancer.
  50. (2003). Matrix metalloproteinase inhibitor reversion-inducing cysteine-rich protein with Kazal motifs – A prognostic marker for good clinical outcome in human breast carcinoma.
  51. (2003). Metastasis suppression: the evolving role of metastasis suppressor genes for regulating cancer cell growth at the secondary site.
  52. (2001). Metastasis suppressor gene KiSS1 encodes peptide ligand of a G-protein-coupled receptor.
  53. (2006). Metastasis suppressor proteins: Discovery, Molecular mechanisms and Clinical Application.
  54. (2007). Metastasis suppressors and their roles in breast carcinoma.
  55. (2007). Metastasis: recent discoveries and novel treatment strategies.
  56. (1990). Metastatic inefficiencyAdv Cancer Res.
  57. (2000). Methylation patterns of the E-cadherin 5′ CpG island are unstable and reflect the dynamic, heterogeneous loss of E-cadherin expression during metastatic progression.
  58. (2007). Microarray analysis reveals potential mechanisms of BRMS1-mediated metastasis suppression. Clin Exp Metastasis
  59. (1999). Mitogen-activated protein kinase kinase 4/stress-activated protein/Erk kinase 1 (MKK4/SEK1), a prostate cancer metastasis suppressor gene encoded by human chromosome 17. Cancer Res 59:5483–5487
  60. (2002). Mitogen-induced, FAK-dependent tyrosine phosphorylation of the SSeCKS scaffolding protein.
  61. (2002). Mitogenactivated protein kinase kinase 4 (MKK4) acts as a metastasis suppressor gene in human ovarian carcinoma.
  62. (2001). Mitogenactivated protein kinase kinase 4 metastasis suppressor gene expression is inversely related to histological pattern in advancing human prostatic cancers.
  63. ML et al (2007) Nm23-H1 homologs suppress tumor cell motility and anchorage independent growth. Clin Exp Metastasis.
  64. (2007). Morphogens, morphostats, microarchitecture and malignancy.
  65. (2007). Multi-step pericellular proteolysis controls the transition from individual to collective cancer cell invasion.
  66. Navenot J-M et al (2007) KISS1 metastasis suppressor secretion, multiple organ metastasis suppression, and maintenance of tumor dormancy.
  67. (1998). Nm23 and tumour metastasis: basic and translational advances. Biochem Soc Symp 63:261–271
  68. (2006). Nm23-H1: a metastasisassociated gene.
  69. (2000). Nm23/nucleoside diphosphate kinase in human cancers.
  70. (1988). Organ specificity of tumor metastasis: role of preferential adhesion, invasion and growth of malignant cells at specific secondary sites. Cancer Metastasis Rev 7:143–188
  71. (1990). Organpreference of metastasis. The role of endothelial cell adhesion molecules. Cancer Metastasis Rev 9:175–189
  72. (2003). Overexpression of cadherins suppresses pulmonary metastasis of osteosarcoma in vivo.
  73. Pang ALY et al (2005) Downregulation of metastasis suppressor genes in malignant pheochromocytoma.
  74. (1986). Primary rat embryo cells transformed by one or two oncogenes show different metastatic potentials.
  75. (2006). Reassessing epithelial to mesenchymal transition as a prerequisite for carcinoma invasion and metastasis.
  76. (2003). RECK: a novel suppressor of malignancy linking oncogenic signaling to extracellular matrix remodeling. Cancer Metastasis Rev
  77. (2007). Recklessness as a hallmark of aggressive cancer.
  78. (2006). Reduced expression of the breast cancer metastasis suppressor 1 mRNA is correlated with poor progress in breast cancer.
  79. (2004). Reduced metastasissuppressor gene mRNA-expression in breast cancer brain metastases.
  80. (2005). Regulation of matrix metalloproteinase 9 expression by Epstein-Barr virus nuclear antigen 3C and the suppressor of metastasis Nm23-H1.
  81. (1998). Regulation of matrix metalloproteinase-9 and inhibition of tumor invasion by the membrane-anchored glycoprotein RECK.
  82. Rinker-Schaeffer CW et al (1995) KAI1, a metastasis suppressor gene for prostate cancer on human chromosome 11p11.2.
  83. (1982). Seed and soil” revisited: mechanisms of sitespecific metastasis.
  84. (2007). Signalling via integrins: Implications for cell survival and anticancer strategies.
  85. (2006). Silencing of the metastasis suppressor RECK by RAS oncogene is mediated by DNA methyltransferase 3b-induced promoter methylation.
  86. (2000). SSeCKS, a major protein kinase C substrate with tumor suppressor activity, regulates G (1)–>S progression by controlling the expression and cellular compartmentalization of cyclin D.
  87. Steinberg MS(2004) Cadherin-mediated cell–cell adhesion and tissue segregation in relation to malignancy.
  88. (2006). Suppression of human ovarian carcinoma metastasis by the metastasis-suppressor gene, BRMS1.
  89. (2005). Suppression of metastatic colonization by the context-dependent activation of the c-jun
  90. Surendran S et al (2006) KAI1/CD82 suppresses tumor invasion by MMP9 inactivation via TIMP1 up-regulation in the H1299 human lung carcinoma cell line.
  91. (2005). The fallacy of epithelial mesenchymal transition in neoplasia
  92. (2006). The KISS1 metastasis suppressor: mechanistic insights and clinical utility.
  93. (2001). The membraneanchored MMP inhibitor RECK is a key regulator of extracellular matrix integrity and angiogenesis.
  94. (2005). The mesenchymal cell, its role in the embryo, and the remarkable signaling mechanisms that create it.
  95. (2006). The problem of cancer dormancy – understanding the basic mechanisms and identifying therapeutic opportunities.
  96. (2007). The role of epithelial– mesenchymal transition in cancer pathology.
  97. (2001). The Src-suppressed C kinase substrate, SSeCKS, is a potential metastasis inhibitor in prostate cancer.
  98. (2004). Tissue inhibitors of metalloproteinase 2 inhibits endothelial cell migration through increased expression of RECK.
  99. (1998). Tombler E et al
  100. (2006). Transfection of nm23-H1 increased expression of beta-Catenin, E-Cadherin and TIMP-1 and decreased the expression of MMP-2, CD44v6 and VEGF and inhibited the metastatic potential of human non-small cell lung cancer cell line L9981.
  101. (2003). Tumour-cell invasion and migration: Diversity and escape mechanisms.
  102. Vandenbogaerde A et al (2001) The metastasis suppressor gene KiSS-1 encodes kisspeptins, the natural ligands of the orphan G protein-coupled receptor GPR54.
  103. (2006). Vander Griend DJ et al
  104. Winnischofer SMB et al (2006) Downregulation of the RECK-tumor and metastasis suppressor gene in glioma invasiveness.
  105. Zhang XA (2006) KAI1/CD82, a tumor metastasis suppressor.
  106. Zhao ZH et al (2007) Correlation of matrix metalloproteinase suppressor genes RECK, VEGF, and CD105 with angiogenesis and biological behavior in esophageal squamous cell carcinoma.

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.